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Abstract
A dry extract from the roots of rhapontic rhubarb (extract Rheum rhaponticum (L.); ERr) has been commercially
available in Germany for over two decades to treat menopausal symptoms. However, the molecular basis of its
clinical effectiveness remains obscure. This article reviews the in vitro and in vivo data of its estrogenic actions, par-
ticularly those mediated by estrogen receptor-b (ERb).
Background
A dry extract from the roots of rhapontic rhubarb
(extract Rheum rhaponticum (L.); ERr; Dahuang)c o n -
sists mainly of rhaponticin (<90%) and aglycones (5%) of
rhaponticin and desoxyrhaponticin (Figure 1). In plants,
these natural hydroxystilbene compounds share a com-
mon biosynthetic pathway with resveratrol which is the
first stilbene compound produced from p-coumaroyl-
CoA catalysed by a selective stilbene synthesis. All other
hydroxystilbenes in Rheum rhaponticum are derivatives
of resveratrol [1].
No adverse events have been observed in human appli-
cations of ERr although the synthetic estrogen diethylstil-
bestrol with a structural similarity of hydroxystilbenes
exerts deleterious transplacental effects in humans [2,3].
In both sexes of the dogs, a dosage of 1000 mg/kg body
weight per day produced no adverse events [4].
Effectiveness of ERr in treating menopause
Since 1993 when ERr was first used in human to treat
menopausal symptoms, and before when it used to treat
women with child bearing potential suffering from oli-
gomenorrhea or amenorrhea, no severe adverse events
have been reported [5]. Ovarian failure during meno-
pausal transition evokes a variety of symptoms. Postme-
nopause is established after 12 months of amenorrhea
[6]. Perimenopause is the period of time (up to five
years) prior to the last menstruation. About 80% of
menopausal women suffer fromh o tf l u s h e s ,s w e a t i n g ,
heart complaints, sleep disturbances, depression, anxiety,
physical/mental exhaustion, sexual problems, urinary
tract complaints and vaginal dryness.
While hormone therapy (HT) effectively relieves
menopausal symptoms, many women seek alternative
treatments due to increased risks for breast [7] and
endometrial cancer [8] associated with HT, as well as
venous thromboembolism. The effectiveness of ERr to
treat menopausal symptoms was validated by a 3-month
prospective randomized controlled trial on 54 perimeno-
pausal women with climacteric complaints receiving a
daily dose of 4 mg of ERr. The treatment with ERr after
12 weeks significantly reduced the Menopause Rating
Scale II symptoms as compared to control. After four
weeks of treatment, the number and severity of hot
flushes were decreased. After 12 weeks the overall
menopause-related quality of life was significantly better
in ERr-treated women than in those who received pla-
cebo. Importantly, no difference was observed in gyne-
cological findings including endometrial biopsies,
bleeding weight, blood pressure and tested laboratory
safety parameters. No adverse events were detected in
relation to ERr intake [9]. ERr is effective in reducing
anxiety in perimenopausal women according to the
Hamilton Anxiety Scale [9].
Continued intake of ERr for 48 and 96 weeks demon-
strated long-term safety of ERr as no endometrial hyper-
plasia was detected, and no adverse events related to
ERr occurred [5].
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symptoms during perimenopause in women and
improves their health-related quality of life [9,10].
Estrogenic activities of ERr
Clinical observations suggest that the mode of action of
ERr is similar to that of hormones (i.e., estrogens).
Estrogenic activities of ERr were assessed at biochem-
ical, molecular and cellular as well as organism levels.
Ligand binding assays and uterotrophic assays are two
major methods to investigate the estrogenic activities of
ERr. Bound estrogen receptors (ERs) usually modify
transcriptional activity of target genes in a target cell.
This process may be investigated by reporter gene assays
in which a target cell is transfected by an expression
plasmid for the ER of interest and a reporter gene con-
struct, e.g. luciferase, whereby functional activity of ERs
is quantified in target cells [11]. Finally, an organism as
a whole has a high metabolic capacity. A compound
given to an organism may be subject to its metabolism
thereby rendering its activity. Therefore, results obtained
in vitro must be verified in vivo. Ovariectomized female
rodent is the recommended animal model for estrogen-
related studies [12,13]. If a compound is administered to
ovariectomized rodents and exhibits estrogenic activities,
uterine growth will be stimulated [14,13].
Ligand binding assays of ERr
Ligand binding affinity for rhapontigenin and desoxyrha-
pontigenin, the aglycones of the major constituents of
ERr, was determined by fluorescence polarisation
according to Mueller et al.[ 1 5 ] .A st h ea s s a yd o e sn o t
tolerate complex substance mixture of the entire extract,
the ligand binding affinity of the total extract cannot be
determined. Both substances exhibit a weak binding affi-
nity to either estrogen receptor a (ERa)o re s t r o g e n
receptor b (ERb) with a slight preference for ERb (Table
1) which is typical in a number of phytestrogens [11].
This weak binding preference suggests that the stimu-
lation of cell-based reporter genes is equally potent for
both receptors. Rhapontigenin and desoxyrhapontigenin
almost only act on ERb. ERr extract activates reporter
gene activity through ERb in HEC-1B endometrial ade-
nocarcinoma cells and an endometrial specific reporter
gene construct (mC3-tk-Luc) [16]. In a study using
bone-derived U2OS cells and a reporter gene construct
((ERE)2-t-Luc), a weak activation of the reporter gene
through ERa by the ERr extract and the two hydroxys-
tilbenes was detected, whereas a strong activation of
ERb-dependent reporter gene by the ERr extract and
the two hydroxystilbenes was observed [17].
The strong ERb specificity observed in cell-based
assays cannot be explained by the weak binding prefer-
ence. A reasonable explanation might be due to
recruitment of co-factors upon ligand binding [18].
Moreover, two other factors may be attributed to the
differences in ligand binding and transcriptional activa-
tion. Firstly, there is a second binding site for sub-
stances such as tamoxifen in the co-activator groove of
the ERb, and thus direct antagonistic co-activator
receptor interaction is possible [19,20]. Whether this
effect can be mimicked by ERr or its constituents
remains to be investigated. Secondly, ligand binding
does not affect the mobility of ERb, but significantly
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Figure 1 Structure of hydroxystilbenes.
Table 1 Relative binding affinities of major constituents
of ERr and estradiol
Substance IC50 ERa IC50 ERb Fold preference for
ERb
Estradiol 8 × 10
-9 6.7 × 10
-9 0.84
Trans-rhapontigenin 1.2 × 10
-5 5.6 × 10
-6 2.14
Desoxyrhapontigenin 2.6 × 10
-5 2.8 × 10
-5 1.1
Note:
Relative binding affinities of trans-rhapontigenin and desoxyrhapontigenin
were assessed by a fluorescence polarization assay. IC50 values of compounds
in comparison to estradiol and relative preference for the receptor subtypes
are shown.
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pure anti-estrogen fulvestrant or the selective estrogen
receptor modulator (SERM) raloxifen [21], whether
and how ERr and/or its constituents influence(s)
nuclear mobility upon binding is still not clear.
Rodent uterotrophic assays of ERr
The absence of an increased uterine wet weight in the in
vivo uterotrophic assay for estrogenicity [14,13] in ovar-
iectomized rats indicates the safety of herbal extracts in
terms of proliferative stimulation within the uterus.
However, the assay data should not be directly extrapo-
lated to human because ovariectomized rodents after a
hormonal decline of 10-14 days are almost void of estro-
gens, while women in menopausal transition and post-
menopause, despite the decline of ovarian estrogen
production, have measurable estrogen levels in their cir-
culation due to extraovarian estrogen production.
We performed two versions of the 3-day uterotrophic
assay. In version 1, we tested four doses of ERr in com-
parison to the positive control estradiol with 0.1 mg/kg
body weight per day as a therapeutically dose and three
pharmacological doses (1, 10 and 100 mg/kg body
weight per day) for safety considerations. In version 2,
the same dose range of ERr was tested in a combinator-
ial treatment in the presenceo fl o wd o s e so fe s t r o g e n s
(0.5 μg/kg body weight per day) to mimic the hormone
levels in menopausal women [22]. Our results demon-
strated two key features of ERr in the uterus of ovariec-
tomized rats: (1) none of the tested doses of the extract
if given alone stimulated uterotrophy (Table 2) or mar-
ker gene expression associated with proliferative events
(data not shown); (2) treatment of ovariectomized rats
with combinations of low dose estradiol and ERr dose
dependently counteracted estradiol induced uterotrophy,
i.e., the treatment resulted in a decrease in uterus wet
weight (Table 2). This is interesting because both the
uterotrophic response itself and the proliferation of the
rat uterus are mediated by ERa primarily through a
tethering mechanism with activator protein 1(AP-1)
transcription factors [23].
Both in vitro and in vivo data support that ERr and/or
its constituents exhibit(s) SERM-like properties. This
hypothesis is supported by the results of a recent study
in which three synthetic SERMs were comparatively
evaluated. Overall, they exhibited mixed agonistic/antag-
onistic properties but shared one common feature,
namely the reduction of the estradiol-stimulated utero-
trophic response [24]. Another study on synthetic
SERM discovered groups of compounds which function-
ally resemble the ERr by exhibiting a binding preference
for ERb and an anti-uterotrophic response in the utero-
trophic assay [25]. Thus, it seems justified to associate
ERr with functional SERM-like properties.
Plants containing hydroxystilbenes in Chinese
medicine
Plants, plant parts or seeds containing hydroxystilbenes
are used in Chinese medicine. Semen Astragali (SA) is a
traditional Chinese tonic which may improve conditions
such as hypertension and liver fibrosis [26-28]. Some
Chinese herbs such as Polygonum cuspidatum, Rheum
tanguticum, Rheum officinale and Rheum coreanum
have been used to alleviate menstrual and postmenopau-
sal symptoms. Polygonum cuspidatum exhibited estro-
genic activities from the anthrachinone emodin and the
modified resveratrol hydroxystilbenes [29]. These studies
suggest a positive role of hydroxystilbenes in the man-
agement of menopausal symptoms.
Conclusion
Neither clinical nor experimental studies observed
adverse events of ERr, e.g., uterine and endometrial
growth and proliferation. Moreover, ERr exerts SERM-
like activities. For function ERb seems to be the more
important ER which in turn has been proven to mediate
e.g., anti-anxiety effects [30].
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Table 2 Relative uterotrophic and anti-uterotrophic
activities
ERr 731 (μg/kg
BW/d)
Estradiol (mg/kg BW/d)
0 0.5 4
0 100 211.5 ±
42.7***
576.6 ± 220***/623.8
± 35.6***
0.1 75.5 ± 9.2/97.3 ±
24.9
189.3 ±
46.1***
-/-
1 85 ± 8.7 162.8 ±
35.1***
-/-
10 103.3 ± 15.2 182.5 ±
31.7***
-/-
100 122.9 ± 13.7/
104.2 ± 19.6
130 ±
18.1*/
++
-/-
Note:
The mean ± SD of uterine wet weights expressed as percentage of untreated
controls are shown. If two values are shown, they represent means ± SD from
two independent experiments.
*P < 0.05, ***P < 0.001: statistical significance (Student’s t-test) if compared to
untreated controls
++P < 0.01: statistical significance (Student’s t-test) if compared to low dose
estradiol treatment (0.0005 mg/kg BW/d)
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